Treatment of Misophonia with Risperidone in a Patient with Autism Spectrum Disorder

Pan, Eric J.; Weleff, Jeremy; Anand, Akhil; Barnett, Brian S.

doi:10.1155/2022/3169834

Cited by 3 publications

(2 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…While the A-Miso-S score was 15 when the patient did not take propranolol, the A-Miso-S score was recorded as 2 when the patient took propranolol (Webb 2022). Pan et al (2022) reported a 32-year-old male patient with autism spectrum disorder and severe misophonia who experienced behavioral outbursts in response to trigger sounds. It was noted that the patient, who was given 2 mg risperidone twice a day, felt less irritable and could tolerate trigger sounds, and his A-Miso-S score decreased from 31 to 5 (Pan et al 2022).…”

Section: Pharmacological Treatmentsmentioning

confidence: 99%

Current Trends in the Treatment of Misophonia

KÖROĞLU,

DURAT

2024

Psikiyatride Güncel Yaklaşımlar

View full text Add to dashboard Cite

Misophonia is a disorder characterized by emotional and physiological responses that occur in response to certain auditory stimuli. Visual, tactile, and olfactory stimuli, primarily oral and nasal sounds such as eating, nose, and respiratory sounds, reveal misophonic responses. People with misophonia may have difficulty in social interactions, and work or school performance may be adversely affected. Misophonia symptoms can also cause anxiety, depression, and other mental health problems. Physiological reactions in the body, such as pain, sweating, tachycardia, hot flashes, and breathing difficulties, negatively affect people's physical health. For this reason, people's physical and mental health and quality of life are significantly affected. The absence of agreed diagnostic criteria for the diagnosis of misophonia and the lack of sufficient data to classify it as a psychiatric disorder has led to the lack of validated treatment guidelines. However, there are treatment recommendations discussed in the literature for misophonia, which has a prevalence of 20% in a limited number of studies and negatively affects the functionality of the individual. In the management of misophonia, tinnitus re-education therapy (TRT) was used as audiological treatment, antidepressants, and anxiolytics were used as pharmacological treatment and cognitive behavioral therapies were used as therapy. Other suggested treatment recommendations are neural remodeling technique, sequential remodeling hypnotherapy, trauma prevention technique, and trauma and tension reduction exercises. This review aims to present the treatment approaches available in the literature together and to understand the need for experimental evidence for treatment methods.

show abstract

Section: Pharmacological Treatmentsmentioning

confidence: 99%

Current Trends in the Treatment of Misophonia

KÖROĞLU,

DURAT

2024

Psikiyatride Güncel Yaklaşımlar

View full text Add to dashboard Cite

show abstract

“…Thus far, no randomized trials have assessed the effects of any medication on misophonia or misokinesia symptoms. Published reports suggest that antidepressants [ 6 , 7 ], beta-blockers such as propranolol [ 8 ], and mood-stabilizing antipsychotics such as risperidone [ 9 , 10 ] may alleviate symptoms in some cases. Potent psychotomimetic drugs, such as psilocybin, ketamine, and MDMA, hold theoretical potential for addressing some of the core symptoms of misophonia and misokinesia, although this is still a hypothesis that will require clinical assessment [ 11 ].…”

Section: Introductionmentioning

confidence: 99%

Steroids for the Treatment of Misophonia and Misokinesia

Webb,

Williamson

2024

Case Reports in Psychiatry

View full text Add to dashboard Cite

Misophonia and misokinesia are disorders characterized by intensely negative physical and emotional reactions to specific auditory and visual stimuli. The availability of effective treatments, especially pharmacological ones, is limited. This report presents a case of a 35-year-old male with severe misophonia and misokinesia who experienced nearly complete resolution of symptoms while undergoing high-dose steroid therapy for an unrelated muscular injury. Two days after starting a 20 mg oral prednisone taper pack (in which the steroid dose is reduced by 4 mg daily), his Amsterdam Misophonia Scale (A-Miso-S) score drastically reduced from a baseline of 23 (i.e., extreme symptoms) to 1, with symptom relief persisting for approximately 2 weeks after completing the taper. Months later, a daily dose of prednisone (4 mg) was reintroduced. This again resulted in a marked reduction in symptoms (A-Miso-S of 6), enabling him to resume working in an office setting despite his triggers. Symptom improvement remained stable over several months. This case raises the possibility of the steroid prednisone as a novel treatment for misophonia and misokinesia. However, further investigation is needed to determine the generalizability of this observation.

show abstract

Olanzapine/risperidone

2023

Reactions Weekly

View full text Add to dashboard Cite

Treatment of Misophonia with Risperidone in a Patient with Autism Spectrum Disorder

Cited by 3 publications

References 25 publications

Current Trends in the Treatment of Misophonia

Current Trends in the Treatment of Misophonia

Steroids for the Treatment of Misophonia and Misokinesia

Olanzapine/risperidone

Contact Info

Product

Resources

About